Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $546.3 million.

  • United Therapeutics' Total Current Liabilities fell 3745.13% to $546.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $546.3 million, marking a year-over-year decrease of 3745.13%. This contributed to the annual value of $738.1 million for FY2024, which is 824.22% down from last year.
  • Latest data reveals that United Therapeutics reported Total Current Liabilities of $546.3 million as of Q3 2025, which was down 3745.13% from $527.1 million recorded in Q2 2025.
  • United Therapeutics' Total Current Liabilities' 5-year high stood at $873.4 million during Q3 2024, with a 5-year trough of $292.6 million in Q1 2022.
  • In the last 5 years, United Therapeutics' Total Current Liabilities had a median value of $370.3 million in 2023 and averaged $519.2 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 16512.63% in 2024, then tumbled by 3745.13% in 2025.
  • Over the past 5 years, United Therapeutics' Total Current Liabilities (Quarter) stood at $305.4 million in 2021, then increased by 12.38% to $343.2 million in 2022, then soared by 134.38% to $804.4 million in 2023, then fell by 8.24% to $738.1 million in 2024, then dropped by 25.99% to $546.3 million in 2025.
  • Its last three reported values are $546.3 million in Q3 2025, $527.1 million for Q2 2025, and $721.5 million during Q1 2025.